Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
49
CKPT Quote, Financials, Valuation and Earnings
Last price:
$3.53
Seasonality move
:
-0.49%
Day range:
$3.41 - $3.65
52-week range:
$1.38 - $4.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
502.9K
Avg. volume:
1.9M
1-year change:
94.65%
Market cap:
$177.8M
Revenue:
$103K
EPS (TTM):
-$1.84
Analysts' Opinion
-
Consensus RatingCheckpoint Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Checkpoint Therapeutics has an estimated upside of 394.51% from its current price of $3.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.64.
Fair Value
-
According to the consensus of 0 analysts, Checkpoint Therapeutics has 394.51% upside to fair value with a price target of -- per share.
CKPT vs. S&P 500
-
Over the past 5 trading days, Checkpoint Therapeutics has underperformed the S&P 500 by -4.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Checkpoint Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Checkpoint Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Checkpoint Therapeutics reported revenues of $41K.
Earnings Growth
-
Checkpoint Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Checkpoint Therapeutics reported earnings per share of -$0.23.
Enterprise value:
173M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-632.35%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-16275.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $134K | $171K | -- | $31K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$71.5M | -$58.6M | -$37.5M | -$7.7M | -$9.7M | |
| EBITDA | -$71.5M | -$58.6M | -$37.5M | -$7.7M | -$9.7M | |
| Diluted EPS | -$8.65 | -$4.54 | -$1.84 | -$0.29 | -$0.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $42.6M | $61M | $21.6M | $2.2M | $5.2M | |
| Total Assets | $42.6M | $61M | $21.6M | $2.2M | $5.2M | |
| Current Liabilities | $6.4M | $13M | $23M | $21.3M | $17.8M | |
| Total Liabilities | $6.4M | $13M | $23M | $21.3M | $17.8M | |
| Total Equity | $36.2M | $48M | -$1.3M | -$19M | -$12.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.7M | -$56.1M | -$30.8M | -$14.8M | -$11.2M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $12M | $37.4M | $33.7M | $9.1M | $11M | |
| Free Cash Flow | -$51.7M | -$56.1M | -$30.8M | -$14.8M | -$11.2M | |
CKPT
Sector
Market Cap
$177.8M
$46.1M
Price % of 52-Week High
80.89%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-26.37%
-0.6%
1-Year Price Total Return
94.65%
-30.52%
Beta (5-Year)
1.340
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.58
200-day SMA
Buy
Level
$2.44
Bollinger Bands (100)
Buy
Level
2.21 - 3.65
Chaikin Money Flow
Sell
Level
-99.3M
20-day SMA
Sell
Level
$3.89
Relative Strength Index (RSI14)
Sell
Level
48.78
ADX Line
Sell
Level
25.65
Williams %R
Neutral
Level
-54.7945
50-day SMA
Buy
Level
$3.59
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
38M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-114.6489)
Sell
CA Score
(Annual)
Level (-35.9435)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (42.5944)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Stock Forecast FAQ
In the current month, CKPT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CKPT average analyst price target in the past 3 months is --.
-
Where Will Checkpoint Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Checkpoint Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Checkpoint Therapeutics?
Analysts are divided on their view about Checkpoint Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Checkpoint Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Checkpoint Therapeutics's Price Target?
The price target for Checkpoint Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CKPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Checkpoint Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CKPT?
You can purchase shares of Checkpoint Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Checkpoint Therapeutics shares.
-
What Is The Checkpoint Therapeutics Share Price Today?
Checkpoint Therapeutics was last trading at $3.53 per share. This represents the most recent stock quote for Checkpoint Therapeutics. Yesterday, Checkpoint Therapeutics closed at $3.64 per share.
-
How To Buy Checkpoint Therapeutics Stock Online?
In order to purchase Checkpoint Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
